Chiome Bioscience Inc.
Notice of Conclusion of Joint Research Agreement on AI-driven Drug Discovery with FRONTEO
Commencement of joint research on AI-driven drug discovery with FRONTEO. By integrating DDAIF from FRONTEO with Kaion's antibody discovery technology DoppeLib, the project aims to establish a new drug discovery platform that seamlessly progresses from target exploration to creation and validation of antibody candidates. Expected impact on the 2026 fiscal year results is minor.
Key Figures
- Date of conclusion of joint research agreement: 2026-09-03
- Impact on 2026 fiscal year results: minor
- Partner: FRONTEO
AI要約
Section heading
This news release is a business update announcing the conclusion of a joint research agreement with FRONTEO on AI-driven drug discovery. The joint research aims to establish a new drug discovery platform by integrating FRONTEO's AI-assisted drug discovery service DDAIF with Kaion's antibody drug development technology DoppeLib, advancing from target discovery to creation and validation of antibody candidates in a continuous process.
Section 2 heading
Looking ahead, multiple themes will be pursued under the joint research, with the goal of creating and deriving bispecific antibody candidates within fiscal year 2027. At the same time, application to the IDD business is also contemplated, with expectations for long-term competitive strength and profitability.
Chiome Bioscience Inc.
Company overview · Stock price · Financial data · All IR
